JPWO2022154127A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022154127A5
JPWO2022154127A5 JP2022575671A JP2022575671A JPWO2022154127A5 JP WO2022154127 A5 JPWO2022154127 A5 JP WO2022154127A5 JP 2022575671 A JP2022575671 A JP 2022575671A JP 2022575671 A JP2022575671 A JP 2022575671A JP WO2022154127 A5 JPWO2022154127 A5 JP WO2022154127A5
Authority
JP
Japan
Prior art keywords
group
antibody
salt
arylene
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022575671A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022154127A1 (https=
JP7670072B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/001617 external-priority patent/WO2022154127A1/ja
Publication of JPWO2022154127A1 publication Critical patent/JPWO2022154127A1/ja
Publication of JPWO2022154127A5 publication Critical patent/JPWO2022154127A5/ja
Priority to JP2025068381A priority Critical patent/JP2025111561A/ja
Application granted granted Critical
Publication of JP7670072B2 publication Critical patent/JP7670072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022575671A 2021-01-18 2022-01-18 化合物またはその塩、およびそれらにより得られる抗体 Active JP7670072B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025068381A JP2025111561A (ja) 2021-01-18 2025-04-17 化合物またはその塩、およびそれらにより得られる抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021005763 2021-01-18
JP2021005763 2021-01-18
PCT/JP2022/001617 WO2022154127A1 (ja) 2021-01-18 2022-01-18 化合物またはその塩、およびそれらにより得られる抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025068381A Division JP2025111561A (ja) 2021-01-18 2025-04-17 化合物またはその塩、およびそれらにより得られる抗体

Publications (3)

Publication Number Publication Date
JPWO2022154127A1 JPWO2022154127A1 (https=) 2022-07-21
JPWO2022154127A5 true JPWO2022154127A5 (https=) 2025-01-27
JP7670072B2 JP7670072B2 (ja) 2025-04-30

Family

ID=82448210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022575671A Active JP7670072B2 (ja) 2021-01-18 2022-01-18 化合物またはその塩、およびそれらにより得られる抗体
JP2025068381A Pending JP2025111561A (ja) 2021-01-18 2025-04-17 化合物またはその塩、およびそれらにより得られる抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025068381A Pending JP2025111561A (ja) 2021-01-18 2025-04-17 化合物またはその塩、およびそれらにより得られる抗体

Country Status (8)

Country Link
US (1) US20240000964A1 (https=)
EP (1) EP4279502A4 (https=)
JP (2) JP7670072B2 (https=)
KR (1) KR20230133289A (https=)
CN (1) CN116761819A (https=)
AU (1) AU2022207278A1 (https=)
CA (1) CA3208290A1 (https=)
WO (1) WO2022154127A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020090979A1 (ja) * 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
WO2023234416A1 (ja) 2022-06-02 2023-12-07 味の素株式会社 親和性物質、化合物、抗体およびそれらの塩

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2232601A1 (en) * 1995-09-22 1997-03-27 Immunomedics, Inc. Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
ITMI20031855A1 (it) * 2003-09-29 2005-03-30 Isagro Ricerca Srl Derivati di 1,3-dioni aventi attivita' erbicida.
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
DE102004026304B3 (de) 2004-05-28 2005-08-25 Atlas Elektronik Gmbh Prüfverfahren für ein Verfahren zur passiven Gewinnung von Zielparamentern
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
WO2008079897A2 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP5566905B2 (ja) 2007-12-20 2014-08-06 ゼネラル・エレクトリック・カンパニイ 生体分子の選択的放射性標識
CA2841313C (en) 2011-07-19 2023-10-24 Cellmosaic, Llc Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
WO2014144878A2 (en) 2013-03-15 2014-09-18 The Scripps Research Institute Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
EP2821791A1 (en) 2013-07-04 2015-01-07 Université de Strasbourg 3-aryl propiolonitrile compounds for thiol labeling
BR112016012538A2 (pt) * 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
EP3617235B1 (en) 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
CA3103143A1 (en) 2018-06-14 2019-12-19 Ajinomoto Co., Inc. Compound having affinity substance to antibody, cleavable portion, and reactive group, or salt thereof
CN112261954B (zh) 2018-06-14 2025-06-24 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
JPWO2020090979A1 (ja) 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN111253333A (zh) * 2018-11-30 2020-06-09 青岛清原化合物有限公司 N-(1,3,4-噁二唑-2-基)芳基甲酰胺类或其盐、制备方法、除草组合物和应用
CN112098640B (zh) 2020-09-16 2021-12-14 浙江正熙生物技术股份有限公司 荧光蛋白和/或偶联蛋白单克隆抗体标记方法及其试剂盒

Similar Documents

Publication Publication Date Title
JP7644173B2 (ja) 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
EP0115171B1 (en) Conjugate having cytotoxicity and process for the preparation thereof
JPWO2022154127A5 (https=)
KR101988005B1 (ko) 개선된 연결을 갖는 아마톡신-접합체
JPS6121227B2 (https=)
US4543211A (en) Conjugate having cytotoxicity and process for the preparation thereof
JP2021121590A5 (https=)
Sakai et al. Multivalent carbohydrate ligands assembled on a metal template
ITMI970929A1 (it) Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
EP1560600B1 (en) Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
JP2025111561A (ja) 化合物またはその塩、およびそれらにより得られる抗体
HU184736B (en) Process for preparing anticarcinogenic immunoglobuline derivatives
JPWO2023234416A5 (https=)
NZ227644A (en) Compounds for use as linking agents in the forming of conjugates
CN118496347B (zh) 一种用于抗体寡核苷酸偶联的方法
JPWO2021201087A5 (https=)
JPWO2023054706A5 (https=)
JPH0625143B2 (ja) イミダゾリド
CN115215927A (zh) 一种含长链巯基臂的链霉亲和素及制备方法
JPS58167519A (ja) 細胞毒性複合体及びその製造法
JPS6238368B2 (https=)
JPS6219770B2 (https=)
EP0267038A2 (en) Anhydrous enhanced coupling
WO1987004171A1 (fr) Procede de preparation d'un complexe d'anticorps
JPS611622A (ja) 細胞毒性複合体及びその製造法